Adial receives notice of allowance for U.S. patent related to AD04

Adial Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent. The patent, once issued, will expand Adial’s intellectual property protection around its lead investigational drug, AD04, which is designed to treat alcohol use disorder, AUD. The new patent covers additional genotype combinations identified through the Company’s proprietary genetic diagnostic tool, further enhancing the precision medicine approach of AD04.